Hologic
(Nasdaq: HOLX)
and Bayer today announced an international partnership focused on improving breast cancer detection.
The companies teamed up to deliver contrast-enhanced mammography (CEM) solutions across Europe, Canada and Asia Pacific. CEM, a highly sensitive, relatively low-cost breast imaging modality, combines digital mammography with contrast agent administration. It supports breast cancer diagnosis and guides treatment decisions.
Marlborough, Massachusetts-based Hologic said the partnership brings together its mammography gantries with Bayer’s CEM-approved injection systems. It enables the administration of contrast media during a mammography examination, according to a news release. The agreement allows the companies to support radiologists with a comprehensive product package and hands-on training.
“Over the past several years, we’ve seen an increased interest in contrast-enhanced mammography as an additional diagnostic modality. Our partnership with Bayer will enable clinicians around the world to offer CEM as part of the breast cancer diagnostic workflow,” said Tanja Brycker, VP, strategic development, breast and skeletal health and GYN solutions at Hologic.
Brycker called the partnership “a compelling example” of the companies’ commitment to enabling healthier lives.
“Breast cancer is the world’s most prevalent cancer, impacting millions of women and their loved ones around the globe,” said Gerd Krueger, president of radiology at Bayer. “Accurate and timely detection is crucial to improve patient outcomes and save patients’ lives. We are excited to join forces with Hologic to deliver a comprehensive solution to our customers and increase access to an emerging breast imaging modality that can help improve diagnostic accuracy as well as provide an alternative imaging option for many women who need it.”
